• Publications
  • Influence
Experimental oral candidosis in the mouse: microbiologic and histologic aspects.
TLDR
It is reported here that oral colonization by C. albicans can be induced in normal adult mice without the use of any compromising agent and that the animals recover from this mucosal infection following a reproducible pattern.
Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors
TLDR
LY3295668 had a manageable toxicity profile and demonstrated activity in some patients with locally advanced or metastatic solid tumors and the maximum tolerated dose (MTD) was 25 mg BID.
Mast cells in the murine oral mucosa are of the connective tissue-type.
The distribution, histochemistry, and functional properties of oral (cheeks, soft palate, and tongue) mast cells (MC) was compared to those of peritoneal, cutaneous, and intestinal MC. The
Acquired resistance and persistence of Candida albicans following oral candidiasis in the mouse: a model of the carrier state in humans.
TLDR
It is proposed that acquired resistance, in conjunction with low-level persistence of Candida in the model, mimics the carrier state in sensitized humans.
The Minor Salivary Gland Network in Experimental Oral Candidosis
TLDR
Immuno-surveillance mechanisms can be expected to have a synergistic effect with oral bacterial competition in the normal handling of Candida, and indirect evidence suggests that a major host defense mechanism against Candida could involve T lymphocytes.
A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer.
TLDR
LY is an oral, selective competitive inhibitor of checkpoint kinase 1 (Chk1) that is known to increase the anti-tumor efficacy of agents such as gemcitabine.
Abstract CT083: A Phase I/II study of aurora kinase A inhibitor, LY3295668 erbumine (AK-01): Safety as monotherapy in patients with locally advanced or metastatic solid tumors
TLDR
The MTD of LY3295668 erbumine was determined to be 25 mg BID and found to be well tolerated in patients with locally advanced or metastatic solid tumors, and three patients died due to disease progression.
A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer.
3579Background: LY2880070 (LY) is an orally-administered, selective adenosine triphosphate-competitive inhibitor of checkpoint kinase 1 (Chk1). LY blocks the checkpoint response, and Chk1 inhibitio...
Targeting Calcium Release–activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation
TLDR
It is concluded that, in this nonhuman primate model of kidney transplantation, PRCL-02 demonstrated evidence of in vivo immunosuppressive activity but was inferior to tacrolimus treatment with respect to suppressing immune transplant rejection.
...
...